Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluation
- 24 September 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 33 (1), 49-59
- https://doi.org/10.1007/s40273-014-0211-5
Abstract
This study assesses if, and how, existing methods for economic evaluation are applicable to the evaluation of personalized medicine (PM) and, if not, where extension to methods may be required. A structured workshop was held with a predefined group of experts (n = 47), and was run using a modified nominal group technique. Workshop findings were recorded using extensive note taking, and summarized using thematic data analysis. The workshop was complemented by structured literature searches. The key finding emerging from the workshop, using an economic perspective, was that two distinct, but linked, interpretations of the concept of PM exist (personalization by ‘physiology’ or ‘preferences’). These interpretations involve specific challenges for the design and conduct of economic evaluations. Existing evaluative (extra-welfarist) frameworks were generally considered appropriate for evaluating PM. When ‘personalization’ is viewed as using physiological biomarkers, challenges include representing complex care pathways; representing spillover effects; meeting data requirements such as evidence on heterogeneity; and choosing appropriate time horizons for the value of further research in uncertainty analysis. When viewed as tailoring medicine to patient preferences, further work is needed regarding revealed preferences, e.g. treatment (non)adherence; stated preferences, e.g. risk interpretation and attitude; consideration of heterogeneity in preferences; and the appropriate framework (welfarism vs. extra-welfarism) to incorporate non-health benefits. Ideally, economic evaluations should take account of both interpretations of PM and consider physiology and preferences. It is important for decision makers to be cognizant of the issues involved with the economic evaluation of PM to appropriately interpret the evidence and target future research funding.Keywords
This publication has 58 references indexed in Scilit:
- What is personalized medicine: sharpening a vague term based on a systematic literature reviewBMC Medical Ethics, 2013
- Current Methodological Issues in the Economic Assessment of Personalized MedicineValue in Health, 2013
- Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest GroupValue in Health, 2012
- From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmakingCost Effectiveness and Resource Allocation, 2012
- Patient empowerment: The need to consider it as a measurable patient-reported outcome for chronic conditionsBMC Health Services Research, 2012
- Economics of individualization in comparative effectiveness research and a basis for a patient-centered health careJournal of Health Economics, 2011
- The Economic Burden of Incidentally Detected FindingsRadiologic Clinics of North America, 2011
- Points to consider in assessing and appraising predictive genetic testsJournal of Community Genetics, 2010
- Colon cancer screening practices and disclosure after receipt of positive or inconclusive genetic test results for hereditary nonpolyposis colorectal cancerCancer, 2009
- Clearing up the hazy road from bench to bedside: A framework for integrating the fourth hurdle into translational medicineBMC Health Services Research, 2008